A few reason: (i) no Adcom communication (or lack of any info re. AdCom) in the mid-cycle communication … "due" by 7/12 (ii) ICER draft report (7/24) support the use of Vascepa (iii) earlier approval by the FDA
(i) and (ii) have a high probability … the (iii) could happen (by any day after August 1).